Nagai N
Dept. of obstetrics and Gynecology, Hiroshima University School of Medicine, Japan.
Gan To Kagaku Ryoho. 1996 Jul;23(8):1004-9.
The usefulness of prognostic factors in gynecological cancer was evaluated using the oncogenes, tumor suppressor genes and DNA viruses detected with the molecular biological technique. In uterine cervical cancer, HPV types 16 and 18 are considered to have a high oncogenic risk, and are commonly associated with high grade CIN and invasive cancer under persistent HPV infection. C-myc overexpression in advanced stage and p53 mutation in HPV negative case are associated with poor survival. In endometrial cancer, oncogene activation and expression are less frequent than in cervical and ovarian cancer. K-ras point mutation (codon 12) tumors are more aggressive and c-erbB-2 overexpression are associated with metastasis and poor survival. In ovarian cancer, there are numerous abnormalities of oncogenes and tumor suppressor genes. Especially, EGF-R and PDGF-R alpha expression are associated with decreased survival. p53 mutation also decreases survival and response to chemotherapy. Recently. MSH2 (Lynch II syndrome) and BRCA1 gene are known to relate with familial ovarian cancer.
利用分子生物学技术检测到的癌基因、肿瘤抑制基因和DNA病毒,评估了预后因素在妇科癌症中的作用。在子宫颈癌中,16型和18型人乳头瘤病毒(HPV)被认为具有较高的致癌风险,并且在持续性HPV感染情况下通常与高级别宫颈上皮内瘤变(CIN)和浸润癌相关。晚期C-myc过表达以及HPV阴性病例中的p53突变与生存率低相关。在子宫内膜癌中,癌基因激活和表达的频率低于宫颈癌和卵巢癌。K-ras点突变(密码子12)的肿瘤侵袭性更强,c-erbB-2过表达与转移和生存率低相关。在卵巢癌中,存在众多癌基因和肿瘤抑制基因异常。特别是,表皮生长因子受体(EGF-R)和血小板衍生生长因子受体α(PDGF-Rα)表达与生存率降低相关。p53突变也会降低生存率以及化疗反应。最近,已知错配修复蛋白2(MSH2,林奇综合征II型)和乳腺癌1号基因(BRCA1)与家族性卵巢癌有关。